Identifies recurrence and guides critical adjuvant therapy decisions as soon as
2-3 weeks post-surgery.1
Guardant Reveal™ is the first liquid-only test
to detect minimal residual disease (MRD) in
colorectal cancer, now available for breast and
Maximize sensitivity up to 91% with surveillance draws.2
2 to 3 weeks.*
In a post-surgery setting,
Initiate MRD testing to inform critical
3 blood draws,
starting between 3 to
13 weeks after curative
In a surveillance setting,
Monitor circulating tumor DNA (ctDNA) to identify
potential early recurrence.1
Testing time points coincide with the current surveillance guidelines and may be used as a supplement to standard-of-care monitoring for colorectal, breast, and lung cancers.†
Surveillance by cancer type5-7
Clinical surveillance time points over
the first 5 years
Swipe to reveal full TABLE
Types of surveillance by cancer type5-7
- Colorectal cancer:
history & physical exam, CEA,
and CT scan
- Breast cancer:
history & physical exam and mammography
- Lung cancer:
history & physical exam and chest CT scan
In a surveillance analysis of patients receiving curative intent
treatment for colorectal cancer (CRC),
recurrence with up to 91% sensitivity.2
In a preliminary analysis of a limited cohort of patients with early-stage
breast cancer who experienced distant recurrence,
and 100% specificity.3,8‡
A retrospective study of patients at 3 years post-diagnosis
- The pilot study was focused on evaluating
Guardant Reveal and its association with breast cancer recurrence.
- 47 plasma samples from 38 patients with early-stage breast cancer (all subtypes) were collected through the BRandO BiO Registry at 12 or 36 months post-diagnosis and/or at the time of clinical recurrence.
- All recurrence statistics reported are from
patients who exhibited distant recurrence.
| Time of diagnosis |
(Number of samples)
|12 months§ (n=10)|| 36 months |
|At recurrence (n=19)|
One recurred later||;
One order form can cover both monitoring and MRD assessment with results delivered in as few as 2 to 3 weeks.
across the cancer continuum.
Covered by MedicareContact client services ›
For patients with stage II or III CRC whose testing is initiated within 3
months following curative intent therapy.
Easy access to test ordering and
management with simple order forms.
Clear, concise reports.Sign in now ›
Easy and Convenient Sample Collection
A mobile phlebotomy service makesInquire about mobile phlebotomy ›
sample collection as easy and
convenient as possible by meeting
patients at their location.
Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.
*Turnaround time (TAT) varies by cancer type. TAT for colorectal cancer is within 2 weeks of sample receipt. TAT for breast and lung cancers is within 3 weeks of sample receipt.
†For invasive carcinomas and inflammatory breast cancers and non-small cell lung cancer (adenocarcinoma, large cell, and squamous).
‡Sensitivity was calculated based on samples collected before or at recurrence.3
§Samples were collected a median of 11.9 months prior to clinical recurrence (range: 1.8-26.4 months).3
||One ctDNA+ patient did not have a second sample collected at time of recurrence (the other 4 were positive at time of recurrence)—hence 13 total patients experienced clinical recurrence, and 11 had ctDNA detected at or before the time of clinical recurrence detection.3